References
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53.
- Barbjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS): EAU guidelines, edition presented at the EAU Annual Congress Stockholm 2014. Arnhem, The Netherlands: European Association of Urology; 2014; ISBN 978-90-79754-65-6.
- Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette–Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124–9.
- Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37:9–15.
- Dalbagni G, Rechtschaffen T, Herr WH. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette–Guerin therapy? J Urol 1999;162:708–9.
- Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, et al. The value of transurethral bladder biopsy after intravesical bacillus Calmette–Guerin installation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature. J Urol 2012;188:748–53.
- Zein TA, Milad MF. Urine cytology in bladder tumors. Int Surg 1991;76:52–4.
- Raitanen M, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284–9.
- Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. J Urol 2005;66:35–63.
- Rink M, Barbjuk M, Catto J, Jichlinski P, Shariat S, Stenzl A, et al. Hexal aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64:624–38.
- Draga R, Grimbergen MC, Kok E, Jonges TG, van Swol CF, Bosch J. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette–Guérin immunotherapy and mitomycin c intravesical therapy. Eur Urol 2010;57:655–60.
- Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003;44:51–6.